2019
CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072.
Naing A, Thistlethwaite F, Spira A, Garcia-Corbacho J, Randhawa M, Eskens F, O'Neil B, Lavernia J, Uboha N, Hamid O, El-Khoueiry A, Benson B, Garner W, Huels V, Arkenau H, LoRusso P. CX-072, a PD-L1 Probody therapeutic, as monotherapy in patients with advanced solid tumors: Preliminary results of PROCLAIM-CX-072. Journal Of Clinical Oncology 2019, 37: 2513-2513. DOI: 10.1200/jco.2019.37.15_suppl.2513.Peer-Reviewed Original ResearchCutaneous squamous cell carcinomaSquamous cell carcinomaSmall bowel adenocarcinomaCX-072Advanced solid tumorsAdverse eventsSolid tumorsPD-L1Cell carcinomaSkin lesionsAnti-programmed cell death ligand-1 (PD-L1) immunotherapiesGrade 3/4 treatment-related adverse eventsAnal squamous cell carcinomaDeath ligand 1 (PD-L1) immunotherapyStandard curative treatment optionsTreatment-related adverse eventsTriple-negative breast cancerAnti-CTLA4 treatmentPhase 1/2a studyMedian treatment durationCurative treatment optionPD-L1 expressionUnresectable solid tumorsPrior regimensBowel adenocarcinoma
2012
497P Dose-Escalation Phase I Study of Cabazitaxel (CBZ) + Gemcitabine (GEM) in Patients (PTS) with Metastatic or Unresectable Advanced Solid Malignancy
Rixe O, Puzanov I, LoRusso P, Yin J, Doroumian S, Zhi X, Olszanski A. 497P Dose-Escalation Phase I Study of Cabazitaxel (CBZ) + Gemcitabine (GEM) in Patients (PTS) with Metastatic or Unresectable Advanced Solid Malignancy. Annals Of Oncology 2012, 23: ix170. DOI: 10.1016/s0923-7534(20)33059-3.Peer-Reviewed Original ResearchTreatment-emergent AEsAdministration sequenceFebrile neutropeniaMetastatic castration-resistant prostate cancerDose-escalation phase IAntitumour activityCastration-resistant prostate cancerPhase IPreliminary PK dataAdvanced solid malignanciesGrade 4 neutropeniaAlternative dosing regimensDrug-drug interactionsUnresectable solid tumorsDrug administration sequenceStable diseaseHaematological toxicityTaxane combinationsOverall survivalPartial responseAdvanced cancerDosing regimensGEM 1000Study treatmentTolerable combination
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply